{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:10:31Z","timestamp":1794384631729,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03944-y","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:29:05Z","timestamp":1761042545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Jing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"3","key":"3944_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"3944_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jamaoncol.2016.2631","volume":"2","author":"HJ Aerts","year":"2016","unstructured":"Aerts HJ. The potential of Radiomic-Based phenotyping in precision medicine: A review. JAMA Oncol. 2016;2(12):1636\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2631.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3944_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3944_CR4","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1016\/S2352-3026(22)00331-3","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Dai H, Wang Y, et al. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China. Lancet Haematol. 2022;9(12):e942\u201354. https:\/\/doi.org\/10.1016\/S2352-3026(22)00331-3.","journal-title":"Lancet Haematol"},{"issue":"15","key":"3944_CR5","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3259.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3944_CR6","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41598-019-46938-7","volume":"9","author":"Y Vedvyas","year":"2019","unstructured":"Vedvyas Y, McCloskey JE, Yang Y, et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 2019;9(1):10634. https:\/\/doi.org\/10.1038\/s41598-019-46938-7. Published 2019 Jul 23.","journal-title":"Sci Rep"},{"issue":"3","key":"3944_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"9","key":"3944_CR8","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, et al. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240\u20132.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3944_CR9","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Stat 2020 CA: Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"Cancer Stat 2020 CA: Cancer J Clin"},{"issue":"1","key":"3944_CR10","first-page":"7","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Stat 2017 CA: Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"Cancer Stat 2017 CA: Cancer J Clin"},{"issue":"26","key":"3944_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"9","key":"3944_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/bjc.2015.124","volume":"112","author":"B Homet Moreno","year":"2015","unstructured":"Homet Moreno B, Ribas A. Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421\u20137.","journal-title":"Br J Cancer"},{"issue":"21","key":"3944_CR13","doi-asserted-by":"publisher","first-page":"8086","DOI":"10.1002\/cam4.3410","volume":"9","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker. Cancer Med. 2020;9(21):8086\u2013121.","journal-title":"Cancer Med"},{"key":"3944_CR14","doi-asserted-by":"crossref","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol. 2020;8:672.","DOI":"10.3389\/fcell.2020.00672"},{"issue":"1","key":"3944_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3944_CR16","doi-asserted-by":"publisher","first-page":"109996","DOI":"10.1016\/j.biopha.2020.109996","volume":"127","author":"J Qu","year":"2020","unstructured":"Qu J, et al. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomed Pharmacother. 2020;127:109996.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3944_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","volume":"38","author":"M de Miguel","year":"2020","unstructured":"de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38(3):326\u201333.","journal-title":"Cancer Cell"},{"key":"3944_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","volume":"472","author":"W Wang","year":"2020","unstructured":"Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175\u201380.","journal-title":"Cancer Lett"},{"issue":"2","key":"3944_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39(2):167\u201376.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3944_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-Cell therapy in hematologic malignancies: A voyage in progress. Clin Pharmacol Ther. 2020;107(1):112\u201322.","journal-title":"Clin Pharmacol Ther"},{"key":"3944_CR21","doi-asserted-by":"crossref","unstructured":"Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019;10:128.","DOI":"10.3389\/fimmu.2019.00128"},{"key":"3944_CR22","doi-asserted-by":"crossref","unstructured":"Arcangeli S, Falcone L, Camisa B, et al. Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. Front Immunol. 2020;11:1217.","DOI":"10.3389\/fimmu.2020.01217"},{"issue":"1","key":"3944_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Reviews Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Reviews Clin Oncol"},{"key":"3944_CR24","doi-asserted-by":"crossref","unstructured":"Reindl LM, Albinger N, Bexte T, M\u00fcller S, Hartmann J, Ullrich E. Immunotherapy with NK cells: recent developments in gene modification open up new avenues. Oncoimmunology. 2020;9(1):1777651.","DOI":"10.1080\/2162402X.2020.1777651"},{"key":"3944_CR25","doi-asserted-by":"crossref","unstructured":"Agrawal B, Gupta N, Konowalchuk JD. MUC1 Mucin: A Putative Regulatory (Checkpoint) Molecule of T Cells. Front Immunol. 2018;9:2391.","DOI":"10.3389\/fimmu.2018.02391"},{"key":"3944_CR26","doi-asserted-by":"crossref","unstructured":"Supruniuk K, Radziejewska I. MUC1 is an oncoprotein with a significant role in apoptosis (Review). Int J Oncol. 2021;59(3):68.","DOI":"10.3892\/ijo.2021.5248"},{"issue":"S1","key":"3944_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12032-010-9752-4","volume":"28","author":"D Situ","year":"2011","unstructured":"Situ D, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 2011;28(S1):596\u2013604.","journal-title":"Med Oncol"},{"issue":"6","key":"3944_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332\u201342.","journal-title":"Trends Mol Med"},{"issue":"9","key":"3944_CR29","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/cas.14541","volume":"111","author":"Y Baba","year":"2020","unstructured":"Baba Y, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111(9):3132\u201341.","journal-title":"Cancer Sci"},{"issue":"7","key":"3944_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/cancers11071040","volume":"11","author":"Z Chen","year":"2019","unstructured":"Chen Z, et al. Strategies to augment natural killer (NK) cell activity against solid tumors. Cancers. 2019;11(7):1040.","journal-title":"Cancers"},{"issue":"44","key":"3944_CR31","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353.","journal-title":"Oncogene"},{"key":"3944_CR32","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293\u2013301.","journal-title":"Blood"},{"key":"3944_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/sj.leu.2401778","volume":"14","author":"H Drexler","year":"2000","unstructured":"Drexler H, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia\u2013lymphoma. Leukemia. 2000;14:777\u201382.","journal-title":"Leukemia"},{"issue":"12","key":"3944_CR34","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"key":"3944_CR35","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.intimp.2019.105695","volume":"74","author":"L Wang","year":"2019","unstructured":"Wang L, Dou M, Ma Q, Yao R, Liu J. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. Int Immunopharmacol. 2019;74:105695.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3944_CR36","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/ijms20112839","volume":"20","author":"R Rotolo","year":"2019","unstructured":"Rotolo R, Leuci V, Donini C, et al. CAR-Based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy. Int J Mol Sci. 2019;20(11):2839. Published 2019 Jun 11.","journal-title":"Int J Mol Sci"},{"key":"3944_CR37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","volume":"54","author":"K Rezvani","year":"2019","unstructured":"Rezvani K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow T Ransplant. 2019;54:785\u20138.","journal-title":"Bone Marrow T Ransplant"},{"issue":"12","key":"3944_CR38","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Z, Ding Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggybac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"3944_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy. 2020;22(10):573\u201380.","journal-title":"Cytotherapy"},{"issue":"8","key":"3944_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai J, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21(8):914\u201326.","journal-title":"Nat Immunol"},{"issue":"5","key":"3944_CR41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059\u201370.","journal-title":"J Clin Immunol"},{"issue":"6","key":"3944_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"3944_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","volume":"26","author":"M Yu","year":"2018","unstructured":"Yu M, et al. Development of GPC3-Specific chimeric antigen Receptor-Engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018;26(2):366\u201378.","journal-title":"Mol Ther"},{"issue":"6","key":"3944_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 Blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"12","key":"3944_CR45","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-Targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091\u2013101.","journal-title":"CNS Drugs"},{"issue":"6","key":"3944_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"2","key":"3944_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","volume":"26","author":"M Yu","year":"2018","unstructured":"Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z. Development of GPC3-Specific chimeric antigen Receptor-Engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018;26(2):366\u201378.","journal-title":"Mol Ther"},{"issue":"4","key":"3944_CR48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.12602","volume":"96","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol. 2016;96(4):389\u201396.","journal-title":"Eur J Haematol"},{"issue":"18","key":"3944_CR49","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"12","key":"3944_CR50","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563\u201370.","journal-title":"Cytotherapy"},{"issue":"51","key":"3944_CR51","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","volume":"8","author":"BA Williams","year":"2017","unstructured":"Williams BA, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256\u201368.","journal-title":"Oncotarget"},{"issue":"6","key":"3944_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai S, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625\u201332.","journal-title":"Cytotherapy"},{"issue":"6","key":"3944_CR53","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, et al. Adoptive transfer of NKG2D CAR mRNA-Engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114\u201325.","journal-title":"Mol Ther"},{"key":"3944_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"NK","year":"2016","unstructured":"NK\u201392. An \u2018off\u2013the\u2013shelf therapeutic\u2019 for adoptive natural killer cell\u2013based cancer immunotherapy. Cancer Immunol Immunother. 2016;65:485\u201392. https:\/\/doi.org\/10.1007\/s00262-015-1761-x.","journal-title":"Cancer Immunol Immunother"},{"key":"3944_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","volume":"6","author":"DL Hermanson","year":"2015","unstructured":"Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015;6:195.","journal-title":"Front Immunol"},{"issue":"11","key":"3944_CR56","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"Y Wu","year":"2017","unstructured":"Wu Y, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"key":"3944_CR57","doi-asserted-by":"crossref","unstructured":"Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17(1):29.","DOI":"10.1186\/s12943-018-0778-0"},{"issue":"5","key":"3944_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577\u201389.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3944_CR59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3944_CR60","first-page":"67","volume":"4","author":"EL Stewart","year":"2015","unstructured":"Stewart EL, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations\u2014a review. Translational Lung Cancer Res. 2015;4(1):67\u201381.","journal-title":"Translational Lung Cancer Res"},{"issue":"8","key":"3944_CR61","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients withEGFR-Mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u20137.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3944_CR62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"3944_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, et al. Checkpoint inhibitors in metastatic EGFR-Mutated Non-Small cell lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017;12(2):403\u20137.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3944_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","volume":"4","author":"CK Lee","year":"2018","unstructured":"Lee CK, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced Non\u2013Small cell lung carcinoma. JAMA Oncol. 2018;4(2):210.","journal-title":"JAMA Oncol"},{"issue":"7","key":"3944_CR65","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532\u20139.","journal-title":"Ann Oncol"},{"issue":"9","key":"3944_CR66","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1988.6.9.1474","volume":"6","author":"JB S\u00f8rensen","year":"1988","unstructured":"S\u00f8rensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988;6(9):1474\u201380.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3944_CR67","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cncr.22565","volume":"109","author":"AM Chen","year":"2007","unstructured":"Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109(8):1668\u201375.","journal-title":"Cancer"},{"issue":"3","key":"3944_CR68","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/cncr.10687","volume":"95","author":"GL Ceresoli","year":"2002","unstructured":"Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer. 2002;95(3):605\u201312.","journal-title":"Cancer"},{"issue":"2","key":"3944_CR69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195\u20139.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3944_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1602\/neurorx.2.1.15","volume":"2","author":"U Bickel","year":"2005","unstructured":"Bickel U. How to measure drug transport across the Blood-Brain barrier. NeuroRX. 2005;2(1):15\u201326.","journal-title":"NeuroRX"},{"key":"3944_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000493057","volume":"34","author":"A Niranjan","year":"2019","unstructured":"Niranjan A, Lunsford LD, Ahluwalia MS. Targeted therapies for brain metastases. Prog Neurol Surg. 2019;34:125\u201337.","journal-title":"Prog Neurol Surg"},{"issue":"2","key":"3944_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ni.3666","volume":"18","author":"B Engelhardt","year":"2017","unstructured":"Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123\u201331.","journal-title":"Nat Immunol"},{"issue":"4","key":"3944_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1189\/jlb.0710432","volume":"89","author":"B Rossi","year":"2011","unstructured":"Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J Leukoc Biol. 2011;89(4):539\u201356.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"3944_CR74","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/0284186X.2019.1615636","volume":"58","author":"B Bj\u00f8rnhart","year":"2019","unstructured":"Bj\u00f8rnhart B, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953\u201361.","journal-title":"Acta Oncol"},{"issue":"7","key":"3944_CR75","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, et al. Outcome of patients with Non\u2013Small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14(7):1244\u201354.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3944_CR76","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00432-019-02899-y","volume":"145","author":"B Ahn","year":"2019","unstructured":"Ahn B, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3944_CR77","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2217\/imt-2018-0012","volume":"10","author":"P Zhang","year":"2018","unstructured":"Zhang P, et al. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy. 2018;10(11):935\u201349.","journal-title":"Immunotherapy"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03944-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:03:28Z","timestamp":1761048208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03944-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3944"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03944-y","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"30 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Third Affiliated Hospital of Anhui Medical University (Date: 2016.7.1\/No. 2016(2).)Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}